ScreenerHero

QURE uniQure N.V.

NAS · US · Healthcare · Biotechnology · uniqure.com
23.14USD+0.35%Mkt Cap: 1.61B $P/E: —

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which c…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap1.61B USD
Enterprise Value1.34B USD
Revenue (TTM)18.67M USD
Gross Profit14.41M USD
Net Income (TTM)-198.97M USD
Revenue/Share0.30 USD
Last Price23.14 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees221
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-7.62
PEG—
EV/EBITDA-7.33
EV/Revenue71.84
P/S85.67
P/B4.93
EPS (TTM)-4.03
EPS (Forward)-3.03
52W Range
8.73023% of range71.50
52W High71.50 USD
52W Low8.730 USD
Profitability
Gross Margin89.53%
Oper. Margin-872.23%
EBITDA Margin0.00%
Profit Margin-1236.00%
ROE-100.04%
ROA-24.12%
Growth
Revenue Growth11.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-177.96M USD
CapEx (TTM)439.00K USD
FCF Margin-415.49%
FCF Yield-4.83%
Net Debt-258.17M USD
Net Debt/EBITDA1.41
Balance Sheet
Debt/Equity0.32
Current Ratio10.01
Quick Ratio9.79
Book Value/Sh4.67 USD
Cash/Share11.68 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)62.62 USD
Upside (mean)+170.6%
Target Range28.11 USD – 91.92 USD
28.11+170.6% to mean91.92
# Analysts11
Ownership
Shares Out.69.37M
Float57.52M
Insiders1.26%
Institutions98.06%
Short Interest
Short Ratio8.6d
Short % Float14.49%
Short % Out.14.30%
Shares Short9.92M
Short (prev mo.)10.77M
Technical
SMA 5042.86 (-46.0%)
SMA 20029.73 (-22.2%)
Beta1.06
S&P 52W Chg15.78%
Avg Vol (30d)2.60M
Avg Vol (10d)5.50M
Technical Indicators
RSI (14)19.7
MACD-6.0041
MACD Signal-4.2139
MACD Hist.-1.7902
BB Upper56.01 USD
BB Middle36.27 USD
BB Lower16.53 USD
BB Width108.85%
ATR (14)2.848 USD
Vol Ratio (20d)0.52x